Sustain-release Lipid-liquid Crystal Formulations of Pexiganan Against Helicobacter Pylori Infection: in Vitro Evaluation in C57BL/6 Mice

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2024 Jan 11

PMID 38212864

Authors

Kiarash Ghazvini

Hossein Kamali

Hadi Farsiani

Masoud Yousefi

Masoud Keikha

Affiliations

Soon will be listed here.

Abstract

Introduction: The Gram-negative bacterium Helicobacter pylori, H. pylori, is associated with significant digestive disorders. However, the effectiveness of bacterial eradication is declining due to drug resistance. A potent anti-H. pylori activity is shown by the natural antimicrobial peptide pexiganan.

Objective: The current study aimed to evaluate the effectiveness of pexiganan and its lipid-liquid crystals (LLCs) in inducing Helicobacter pylori in mice.

Methods: In this experimental study, H. pylori infection was first induced in C57BL/6 mice. Secondly, the antibacterial efficacy of pexiganan and its LLCs formulations was investigated to eliminate H. pylori infection.

Results: The H. pylori infection could not be completely eradicated by pexiganan peptide alone. However, incorporating pexiganan within the LLC formulation resulted in an increased elimination of H. pylori. Under the H&E strain, the pexiganan-LLCs formulation revealed minimal mucosal alterations and a lower amount of inflammatory cell infiltration in the stomach compared to the placebo.

Conclusion: Clarithromycin was more effective than pexiganan at all tested concentrations. Furthermore, the pexiganan-loaded LLCs exhibited superior efficacy in curing H. pylori infection in a mouse model compared to pexiganan alone. This formulation can enhance H. pylori clearance while mitigating the adverse effects, typically associated with conventional drugs, leading to a viable alternative to current treatment options.

References

Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang T, Hoebeke M . resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021; 70(10):1815-1822. DOI: 10.1136/gutjnl-2021-324032. View

Chen Y, Ma P, Gui S . Cubic and hexagonal liquid crystals as drug delivery systems. Biomed Res Int. 2014; 2014:815981. PMC: 4068036. DOI: 10.1155/2014/815981. View

Iwahori A, Hirota Y, Sampe R, Miyano S, Takahashi N, Sasatsu M . On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Biol Pharm Bull. 1997; 20(7):805-8. DOI: 10.1248/bpb.20.805. View

Neshani A, Zare H, Akbari Eidgahi M, Hooshyar Chichaklu A, Movaqar A, Ghazvini K . Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2018; 24(1):e12555. DOI: 10.1111/hel.12555. View

Zhang X, Jiang A, Ma Z, Li X, Xiong Y, Dou J . The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules. 2015; 20(3):3972-85. PMC: 6272436. DOI: 10.3390/molecules20033972. View

Wimley W, Hristova K . Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011; 239(1-2):27-34. PMC: 3166253. DOI: 10.1007/s00232-011-9343-0. View

Ki M, Lim J, Ko J, Park S, Kim J, Cho H . A new injectable liquid crystal system for one month delivery of leuprolide. J Control Release. 2014; 185:62-70. DOI: 10.1016/j.jconrel.2014.04.034. View

Wang X, Zhang Y, Gui S, Huang J, Cao J, Li Z . Characterization of Lipid-Based Lyotropic Liquid Crystal and Effects of Guest Molecules on Its Microstructure: a Systematic Review. AAPS PharmSciTech. 2018; 19(5):2023-2040. DOI: 10.1208/s12249-018-1069-1. View

Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X . Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond. Int J Mol Sci. 2017; 18(8). PMC: 5578089. DOI: 10.3390/ijms18081699. View

10.

Fan F, Wang Z, Li B, Zhang H . Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: A systematic review and meta-analysis. J Eval Clin Pract. 2019; 26(1):308-315. DOI: 10.1111/jep.13179. View

11.

Schubert J, Woodman R, Mangoni A, Rayner C, Warner M, Roberts-Thomson I . Geospatial analysis of Helicobacter pylori infection in South Australia: Should location influence eradication therapy?. J Gastroenterol Hepatol. 2022; 37(7):1263-1274. PMC: 9543722. DOI: 10.1111/jgh.15832. View

12.

Graham D, Fischbach L . Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59(8):1143-53. DOI: 10.1136/gut.2009.192757. View

13.

De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C . Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19(4):409-14. View

14.

Libster D, Aserin A, Garti N . Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications. J Colloid Interface Sci. 2011; 356(2):375-86. DOI: 10.1016/j.jcis.2011.01.047. View

15.

Baez-Santos Y, Otte A, Mun E, Soh B, Song C, Lee Y . Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate. Int J Pharm. 2016; 514(1):314-321. DOI: 10.1016/j.ijpharm.2016.06.138. View

16.

Seo M, Won H, Kim J, Mishig-Ochir T, Lee B . Antimicrobial peptides for therapeutic applications: a review. Molecules. 2012; 17(10):12276-86. PMC: 6268056. DOI: 10.3390/molecules171012276. View

17.

Nagarajan D, Roy N, Kulkarni O, Nanajkar N, Datey A, Ravichandran S . Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant . Sci Adv. 2019; 5(7):eaax1946. PMC: 6656545. DOI: 10.1126/sciadv.aax1946. View

18.

Lim J, Ki M, Joo M, An S, Hwang K, Park E . An injectable liquid crystal system for sustained delivery of entecavir. Int J Pharm. 2015; 490(1-2):265-72. DOI: 10.1016/j.ijpharm.2015.05.049. View

19.

Shah S, Qaqish R, Patel V, Amiji M . Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol. 1999; 51(6):667-72. DOI: 10.1211/0022357991772952. View

20.

Stevenson C, Bennett D, Lechuga-Ballesteros D . Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci. 2005; 94(9):1861-80. DOI: 10.1002/jps.20435. View